<6-D₁>-salicylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: <6-D₁>-salicylic acid
• 英文别名: salicylic-6-d acid；2-Deuterio-6-hydroxybenzoic acid
• 化学式: C₇H₆O₃
• 分子量: 139.115
• InChiKey: YGSDEFSMJLZEOE-WFVSFCRTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  阿司匹林 在 tris(acetonitrile)(η5-pentamethylcyclopentadienyl)rhodium(III) hexafluoroantimonate 、 重水 、 sodium acetate 作用下， 反应 24.0h， 以65%的产率得到<6-D₁>-salicylic acid
  参考文献：
  名称：

  阳离子RhIII催化D2O中酸性芳族化合物的邻位氘代反应的规程。

  摘要：

  以催化合成的方式将氘直接催化引入芳烃上羧酸导向基团的方法通常需要D2或高催化剂负载量，这使得使用这些方法的成本高昂，无法进行大规模合成（分别是设备和试剂成本）。在本文中，我们提出了一种简化的方法，使用低催化剂负载量的阳离子RhIII和D2O作为氘源和溶剂，并展示了其在各种羧酸底物上进行H / D交换的应用。

  DOI：

  10.1021/acs.orglett.9b02618

文献信息

• Tashiro, Masashi; Tsuzuki, Hirohisa; Matsumoto, Jun-ichi, Journal of Chemical Research, Miniprint, 1989, # 12, p. 2826 - 2851
  作者：Tashiro, Masashi、Tsuzuki, Hirohisa、Matsumoto, Jun-ichi、Mataka, Shuntaro、Nakayama, Kouji、et al.

  DOI：——

  日期：——
• LOCKLEY, W. S., TETRAHEDRON LETT., 1982, 23, N 37, 3819-3822
  作者：LOCKLEY, W. S.

  DOI：——

  日期：——
• HALL, C. R.;LEY, R. V., J. LABELLED COMPOUNDS AND RADIOPHARM., 1983, 20, N 7, 797-801
  作者：HALL, C. R.、LEY, R. V.

  DOI：——

  日期：——
• DEUTERIUM-ENRICHED SILDENAFIL
  申请人：Czarnik Anthony W.

  公开号：US20090062298A1

  公开（公告）日：2009-03-05

  The present application describes deuterium-enriched sildenafil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
• ANTI-MICROBIAL AGENTS AND USES THEREOF
  申请人：Tan Derek Shieh

  公开号：US20090170805A1

  公开（公告）日：2009-07-02

  Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis , rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5′-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.